Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 16.

Journal Article

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian ORCID: 0000-0003-2644-1050, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre ORCID: 0000-0001-5125-6522, Mato, Anthony, Pavlovsky, Miguel A., Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, Hallek, Michael, Assouline, S., Bence-Bruckler, I., Buckstein, R., Fraser, G., Larratt, L., Minuk, L., Villa, D., Angevine, A., Bartlett, N., Bixby, D., Caimi, P., Chanan-Khan, A., Craig, M., Forero-Torres, A., Ganguly, S., Goy, A., Heffner, L., Hermann, R., Lansigan, F., Leis, J., Letzer, J., Link, B., Liu, D., McCaul, K., McGuire, E., Skinner, W., Starodub, A., Stuart, R., Thirman, M., Tirumali, N., Yang, J., Janssens, A., Offner, F., Van den Neste, E., Van Hoof, A., Mayer, J., Novak, J., Trneny, M., Cartron, G., Dartigeas, C., Dilhuydy, M., Ghez, D., Haioun, C., Leblond, V., Salles, G., Balser, C., Cramer, P., Dreger, P., Durig, J., Eckart, M., Heinrich, B., Illmer, T., Jentsch-Ullrich, K., Pfreundschuh, M., Schetelig, J., Schlag, R., Soling, U., Stilgenbaue, S., Anagnostopoulos, A., Dimopoulos, A., Panagiotidis, P., Vrakidou, E., Bairey, O., Ben Yehuda, D., Braester, A., Fineman, R., Herishanu, Y., Nagler, A., Ruchlemer, R., Tadmor, T., Grosicki, S., Homenda, W., Jurczak, W., Pluta, A., Woszczyk, D., Espirito Santo, A., Luis, R., Raposo, J., Viveiros, C., Alexeeva, J., Dunaev, Y., Golubeva, M., Khuageva, N., Loginov, A., Lysenko, I., Osmanov, E., Pavlov, V., Pristupa, A., Proydakov, A., Rossiev, V., Samarina, I., Samoilova, O., Serduk, O., Shneider, T., Udovitsa, D., Voloshin, S., Gayoso, J., Gonzalez, M., Gonzalez Barca, E., Hernandez Rivas, J., Jargue, I., Loscertales, J., Karlsson, C., Sender, M., Aktan, M., Arslan, O., Demirkan, F., Ferhanoglu, B., Kaynar, L., Sayinalp, N., Vaural, F., Yagci, M., Dyagil, I., Kaplan, P., Masliak, Z., Oliynyk, H., Popovska, T., Pylypenko, H., Rekhtman, G., Dearden, C., Morley, N., Moss, P., Rule, S., Pavlovsky, M., Riveros, D., Santucci-Silva, R., Romeo, M., Scheliga, A., Salazar, L., Gomez, D., Ramirez, E. and Jung, C. (2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol., 17 (2). S. 200 - 212. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela and Hallek, Michael (2015). Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chanan-Khan, Asher, Cramer, Paula, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Dilhuydy, Marie Sarah, Goy, Andre ORCID: 0000-0001-5125-6522, Mato, Anthony R., Damle, Rajendra, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Howes, Angela and Balasubramanian, Sriram (2015). Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chanan-Khan, Asher Alban Akmal, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Alexander, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Salman, Mariya, Howes, Angela J. and Hallek, Michael J. (2015). Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. J. Clin. Oncol., 33 (18). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Cramer, Paula, Chanan-Khan, Asher, Fraser, Graeme, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Balasubramanian, Sriram, Howes, Angela and Hallek, Michael (2015). Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, Fraser, Graeme, Santucci-Silva, Rodrigo, Grosicki, Sebastian ORCID: 0000-0003-2644-1050, Dilhuydy, Marie-Sarah, Janssens, Ann, Loscertales, Javier, Rule, Simon, Goy, Andre ORCID: 0000-0001-5125-6522, Traina, Shana, Chan, Eric K. H., Diels, Joris, Sengupta, Nishan, Mahler, Michelle, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher (2018). Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leuk. Lymphoma, 59 (9). S. 2075 - 2085. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fraser, Graeme, Chanan-Khan, Asher, Demirkan, Faith, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy, Dilhuydy, Marie Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlosky, Miguel, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Balasubramanian, Sriram, Howes, Angela and Cramer, Paula (2020). Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Leuk. Lymphoma, 61. S. 106 - 109. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie-Sarah, Loscertales, Javier, Goy, Andre ORCID: 0000-0001-5125-6522, Avigdor, Abraham, Rule, Simon, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela J., Balasubramanian, Sriram and Chanan-Khan, Asher Alban Akmal (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fraser, Graeme A. M., Chanan-Khan, Asher, Demirkan, Fatih, Santucci Silva, Rodrigo, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlovsky, Miguel A., Goy, Andre, Mato, Anthony, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Schuier, Natasha, Balasubramanian, Sriram, Howes, Angela and Cramer, Paula (2020). Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk. Lymphoma, 61 (13). S. 3188 - 3198. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Hallek, Michael, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Phelps, Charles, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher (2017). Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk. Lymphoma, 58. S. 192 - 195. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Hallek, Michael, Kay, Neil E., Osterborg, Anders, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Wan, Ying, Sun, Steven, Zhuang, Sen Hong and Howes, Angela (2015). The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol., 11 (1). S. 51 - 60. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O'Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2019). Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin. Lymphoma Myeloma Leuk., 19 (11). S. 715 - 729. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Kipps, Thomas J., Hillmen, Peter, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Grosicki, Sebastian, Coutre, Steven E., Barrientos, Jacqueline C., Barr, Paul M., Janssens, Ann, Byrd, John C., O'Brien, Susan M., Fraser, Graeme, Jaeger, Ulrich, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Salman, Mariya, Solman, Isabelle, Cheng, Mei, Phelps, Charles, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2016). 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kipps, Thomas J., Mahler, Michelle, Fraser, Graeme, Coutre, Steven, Brown, Jennifer, Barrientos, Jacqueline, Barr, Paul ORCID: 0000-0002-9733-401X, Byrd, John C., O'Brien, Susan, Dilhuydy, Marie Sarah, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher, Salman, Mariya, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle, Hallek, Michael and Hillmen, Peter (2017). Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies. Leuk. Lymphoma, 58. S. 10 - 13. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Lavezzi, Silvia Maria, de Jong, Jan, Neyens, Martine, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Bartlett, Nancy ORCID: 0000-0001-8470-394X, Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Goy, Andre ORCID: 0000-0001-5125-6522, Ganguly, Siddhartha, Salman, Mariya, Howes, Angela, Mahler, Michelle, De Nicolao, Giuseppe and Poggesi, Italo (2019). Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharm. Res., 36 (7). NEW YORK: SPRINGER/PLENUM PUBLISHERS. ISSN 1573-904X

Traina, Shana, Fraser, Graeme, Cramer, Paula, Silva, Rodrigo Santucci, Grosicki, Sebastian, Dilhuydy, Marie Sarah, Mahler, Michelle, Salman, Mariya and Howes, Angela (2015). Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Sat Oct 16 06:56:13 2021 CEST.